{"symbol":"BMY","fiscalQuarter":"Q3-2023","reportDate":"2023-10-26","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2023","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 6.43%","keyNumbers":[{"metric":"EPS","actual":"$2.00","expected":"N/A","surprise":"+13.64%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the continued strength of their pipeline.","They acknowledged challenges in the market but remain focused on long-term goals."],"summary":"Overall, management expressed a cautious optimism about future growth despite current market pressures. They emphasized their commitment to innovation and addressing challenges head-on."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive surprise on EPS, indicating stronger-than-expected profitability. However, the stock fell by 6.43%, likely due to a lack of revenue details and no guidance for the future. Investors may be concerned about market conditions and the company's ability to navigate them.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2023 earnings: EPS beat expectations. Stock down 6.43%. Full breakdown."}}